ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 852,47
-0,44%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) Actualités

CPRX Catalyst Pharmaceuticals Inc

14,97
-0,03 (-0,20%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Catalyst Pharmaceuticals Inc CPRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,03 -0,20% 14,97 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
15,00 14,775 15,05 14,97 15,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202417:17EDGAR2Form 144 - Report of proposed sale of securities
05/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202416:41EDGAR2Form 144 - Report of proposed sale of securities
03/6/202418:22EDGAR2Form 144 - Report of proposed sale of securities
31/5/202422:50EDGAR2Form S-8 - Securities to be offered to employees in employee..
31/5/202422:47EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
31/5/202422:46EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
31/5/202422:43EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
30/5/202422:43EDGAR2Form 8-K - Current report
30/5/202419:41GLOBECatalyst Pharmaceuticals Receives U.S. FDA Approval For..
28/5/202414:03GLOBECatalyst Pharmaceuticals to Participate at the Jefferies..
21/5/202423:28EDGAR2Form 8-K - Current report
08/5/202422:54EDGAR2Form 8-K - Current report
08/5/202422:16GLOBECatalyst Pharmaceuticals Reports Solid First Quarter 2024..
08/5/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/5/202414:00GLOBECatalyst Pharmaceuticals to Participate at the BofA..
22/4/202414:00GLOBECatalyst Pharmaceuticals to Report First Quarter 2024..
28/3/202413:03GLOBECatalyst Pharmaceuticals Announces Support for the Inaugural..
27/3/202413:03GLOBECatalyst Pharmaceuticals to Participate in the 2024 Cantor..
13/3/202412:55GLOBECatalyst Pharmaceuticals Announces AGAMREE® Now Commercially..
05/3/202414:03GLOBECatalyst Pharmaceuticals to Participate at the Barclays 26th..
29/2/202400:03GLOBECatalyst Pharmaceuticals Reports Strong Fourth Quarter and..
27/2/202414:03GLOBECatalyst Pharmaceuticals to Present at MDA Clinical &..
21/2/202415:00GLOBECatalyst Pharmaceuticals Announces Publication of Santhera..
16/2/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:03GLOBECatalyst Pharmaceuticals to Report Fourth Quarter and..
09/1/202423:15EDGAR2Form 8-K - Current report
09/1/202422:05GLOBECatalyst Pharmaceuticals, Inc. Announces Closing of Public..
08/1/202414:10EDGAR2Form 8-K - Current report
05/1/202423:23EDGAR2Form 8-K - Current report
05/1/202423:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202414:02GLOBECatalyst Pharmaceuticals, Inc. Announces Pricing of Public..
04/1/202422:49GLOBECatalyst Pharmaceuticals, Inc. Announces Proposed Public..
03/1/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:18EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
CPRX
Catalyst Pharmaceuticals
COIN
DAXTGBP
TG
B6FA
Bque F C Mtl 04/und Mtn
LSE
44DW
Diageo Cp.23
BIT
P1XMA8
NLBNPIT1XMA8 20240920 1.1
BIT
P1YGR2
NLBNPIT1YGR2 20241220 22
USOTC
BRYGF
Baroyeca Gold and Silver (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés